Limits...
A Novel Point-of-Care BioNanoSensor for Rapid HIV Detection and Treatment Monitoring.

Rozmyslowicz T, deSa J, Lec R, Gaulton GN - J AIDS Clin Res (2015)

Bottom Line: The detection range of the BNS device for the biomarker gp120 displayed a low-end sensitivity of 6.5×10(4) HIV viral particles/ml, while using a small fluid sample (5 µl) and with a reaction time of less then 30 seconds.Performance of this device indicated that the BNS has utility for direct detection of HIV particles prior to, and independent from, antibody formation.The BNS parameters of small sample volume, compact device size, and detection sensitivity indicate that the BNS is potentially useful in the point-of-care and/or home setting for monitoring decisions regarding HIV treatment on a real-time basis.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Pathology and Laboratory Medicine, University of Pennsylvania, School of Medicine, Philadelphia, USA.

ABSTRACT

We report here a new diagnostic approach to the direct detection of HIV in blood or other body fluids that is rapid, sensitive and potentially applicable in a point-of-care setting. The approach follows on the development of a novel BioNanoSensor (BNS) device that utilizes piezoelectric technology to detect the presence of the HIV surface glycoprotein gp120 in a nanoscale format. The detection range of the BNS device for the biomarker gp120 displayed a low-end sensitivity of 6.5×10(4) HIV viral particles/ml, while using a small fluid sample (5 µl) and with a reaction time of less then 30 seconds. Performance of this device indicated that the BNS has utility for direct detection of HIV particles prior to, and independent from, antibody formation. Accordingly, this device holds utility to monitor the status of HIV infection both early after exposure to virus as well as during chronic HIV infection. The BNS parameters of small sample volume, compact device size, and detection sensitivity indicate that the BNS is potentially useful in the point-of-care and/or home setting for monitoring decisions regarding HIV treatment on a real-time basis.

No MeSH data available.


Related in: MedlinePlus

Frequency response change to gp120 binding: The magnitude of sensor frequency change was measured following the addition of gp120, over the range of 0.1–0.4 mg/ml, to the BNS device.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4596080&req=5

Figure 2: Frequency response change to gp120 binding: The magnitude of sensor frequency change was measured following the addition of gp120, over the range of 0.1–0.4 mg/ml, to the BNS device.

Mentions: The sensitivity of the BNS for gp120 detection was next measured by mapping responses to a serial dilution of gp120 concentrations (0.1 – 0.4 µg/µl). The resulting sensitivity curve, shown in Figure 2, predicts a current lower limit of BNS detection at 25 ng/µl gp120.


A Novel Point-of-Care BioNanoSensor for Rapid HIV Detection and Treatment Monitoring.

Rozmyslowicz T, deSa J, Lec R, Gaulton GN - J AIDS Clin Res (2015)

Frequency response change to gp120 binding: The magnitude of sensor frequency change was measured following the addition of gp120, over the range of 0.1–0.4 mg/ml, to the BNS device.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4596080&req=5

Figure 2: Frequency response change to gp120 binding: The magnitude of sensor frequency change was measured following the addition of gp120, over the range of 0.1–0.4 mg/ml, to the BNS device.
Mentions: The sensitivity of the BNS for gp120 detection was next measured by mapping responses to a serial dilution of gp120 concentrations (0.1 – 0.4 µg/µl). The resulting sensitivity curve, shown in Figure 2, predicts a current lower limit of BNS detection at 25 ng/µl gp120.

Bottom Line: The detection range of the BNS device for the biomarker gp120 displayed a low-end sensitivity of 6.5×10(4) HIV viral particles/ml, while using a small fluid sample (5 µl) and with a reaction time of less then 30 seconds.Performance of this device indicated that the BNS has utility for direct detection of HIV particles prior to, and independent from, antibody formation.The BNS parameters of small sample volume, compact device size, and detection sensitivity indicate that the BNS is potentially useful in the point-of-care and/or home setting for monitoring decisions regarding HIV treatment on a real-time basis.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Pathology and Laboratory Medicine, University of Pennsylvania, School of Medicine, Philadelphia, USA.

ABSTRACT

We report here a new diagnostic approach to the direct detection of HIV in blood or other body fluids that is rapid, sensitive and potentially applicable in a point-of-care setting. The approach follows on the development of a novel BioNanoSensor (BNS) device that utilizes piezoelectric technology to detect the presence of the HIV surface glycoprotein gp120 in a nanoscale format. The detection range of the BNS device for the biomarker gp120 displayed a low-end sensitivity of 6.5×10(4) HIV viral particles/ml, while using a small fluid sample (5 µl) and with a reaction time of less then 30 seconds. Performance of this device indicated that the BNS has utility for direct detection of HIV particles prior to, and independent from, antibody formation. Accordingly, this device holds utility to monitor the status of HIV infection both early after exposure to virus as well as during chronic HIV infection. The BNS parameters of small sample volume, compact device size, and detection sensitivity indicate that the BNS is potentially useful in the point-of-care and/or home setting for monitoring decisions regarding HIV treatment on a real-time basis.

No MeSH data available.


Related in: MedlinePlus